Robert Ang

Robert Ang brings more than 20 years of executive leadership, strategy consulting and investing experience in the biopharma industry. He currently serves as the President and Chief Executive Officer of Vor Biopharma, a clinical-stage cell and genome engineering company based in Cambridge, MA where he has led a successful Series B fundraising and a subsequent NASDAQ IPO.

Prior to Vor, Robert was Chief Business Officer at Neon Therapeutics, where he was responsible for strategy, business development, financing, collaborations, intellectual property and other functions, raising over $125M in private financing and $100M in gross proceeds from an IPO. Robert also served as the SVP of Business Development at Bavarian Nordic and was responsible for conducting the licensing transaction between Bavarian Nordic and Bristol-Myers Squibb for PROSTVAC. Robert has operational experience from Cadence Pharmaceuticals and Cure Therapeutics, and venture capital experience at Frazier Healthcare Ventures and Carrot Capital with five investments generating cash-on-cash returns of over three times.

Robert holds a medical degree from the University of Western Australia, trained in general surgery, and received an MBA with Honors from Columbia Business School.